

# Analia Sanchez-Luceros

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3818643/publications.pdf>

Version: 2024-02-01

32  
papers

641  
citations

759233

12  
h-index

610901

24  
g-index

32  
all docs

32  
docs citations

32  
times ranked

776  
citing authors

#	ARTICLE	IF	CITATIONS
1	von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1320-1326.	3.4	121
2	Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 647-651.	1.0	86
3	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 732-739.	3.8	64
4	Patients' perceptions regarding oral anticoagulation therapy and its effect on quality of life. <i>Current Medical Research and Opinion</i> , 2005, 21, 1085-1090.	1.9	58
5	Evaluation of the clinical safety of desmopressin during pregnancy in women with a low plasmatic von Willebrand factor level and bleeding history. <i>Thrombosis Research</i> , 2007, 120, 387-390.	1.7	44
6	Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. , 2000, 63, 192-196.		43
7	A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients. <i>SpringerPlus</i> , 2015, 4, 428.	1.2	34
8	Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history. <i>Thrombosis and Haemostasis</i> , 2010, 104, 984-989.	3.4	20
9	Marked bleeding diathesis in patients with platelet dysfunction due to a novel mutation in <i>RASGRP2</i> , encoding CalDAG-GEFI (p.Gly305Asp). <i>Platelets</i> , 2018, 29, 84-86.	2.3	20
10	Identification of p.W246L As a Novel Mutation in the GP1BA Gene Responsible for Platelet-Type von Willebrand Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 151-160.	2.7	18
11	Prevalence of Fabry Disease in Young Patients with Stroke in Argentina. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 575-582.	1.6	18
12	Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution. <i>Haematologica</i> , 2002, 87, 264-70.	3.5	16
13	Von Willebrand factor (VWF) as a risk factor for bleeding and thrombosis. <i>Hematology</i> , 2012, 17, s150-s152.	1.5	14
14	Type 2A and 2M von Willebrand Disease: Differences in Phenotypic Parameters According to the Affected Domain by Disease-Causing Variants and Assessment of Pathophysiological Mechanisms. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 862-874.	2.7	10
15	Effect of Low-Dose Aspirin on the International Normalized Ratio Variability in Patients with Mechanical Heart Valve Prostheses. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2002, 32, 155-157.	0.3	9
16	PT-VWD posing diagnostic and therapeutic challenges – small case series. <i>Platelets</i> , 2017, 28, 484-490.	2.3	9
17	Morbidity of lupus anticoagulants in children: a single institution experience. <i>Thrombosis Research</i> , 2004, 114, 245-249.	1.7	8
18	Diagnosis and Management of von Willebrand Disease in a Single Institution of Argentina. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 568-575.	2.7	8

#	ARTICLE	IF	CITATIONS
19	C1272F: a novel type 2A von Willebrandâ€™s disease mutation in A1 domain; its clinical significance. Haemophilia, 2012, 18, 112-116.	2.1	7
20	Phenotypic Parameters in Genotypically Selected Type 2B von Willebrand Disease Patients: A Large, Single-Center Experience Including a New Novel Mutation. Seminars in Thrombosis and Hemostasis, 2017, 43, 092-100.	2.7	7
21	Antiphospholipid antibodies and hyperhomocysteinaemia in patients with vascular occlusive disease. Thrombosis and Haemostasis, 2006, 96, 19-23.	3.4	5
22	A new ADAMTS13 missense mutation (D1362V) in thrombotic thrombocytopenic purpura diagnosed during pregnancy. Thrombosis and Haemostasis, 2012, 108, 401-403.	3.4	4
23	Diagnosis of von Willebrand disease in Argentina: a single institution experience. Annals of Blood, 0, 2, 22-22.	0.4	4
24	Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial. Investigational New Drugs, 2020, 38, 1580-1587.	2.6	3
25	Thrombotic microangiopathies: First report of 294 cases from a single institution experience in Argentina. EJHaem, 2021, 2, 149-156.	1.0	3
26	Combined effects of two mutations in von Willebrand disease 2M phenotype. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 162-167.	2.3	2
27	Type 2N von Willebrand disease: Is it always a recessive trait?. Thrombosis Research, 2021, 198, 49-51.	1.7	2
28	Acquired Hemophilia A. Experience Of a Single Center. Blood, 2013, 122, 4781-4781.	1.4	2
29	Clinical profile of the association of P.R1205h and P.R924q in a patient with von Willebrand's disease. Haemophilia, 2013, 19, e180-1.	2.1	1
30	Von Willebrand disease type 2M: Correlation between genotype and phenotype: Comment from Woods et al.. Journal of Thrombosis and Haemostasis, 2022, 20, 1022-1023.	3.8	1
31	Diagnosis and Management of von Willebrand Disease in a Single Institution of Argentina. Seminars in Thrombosis and Hemostasis, 2011, 37, 856-858.	2.7	0
32	C0379 Several polymorphisms in the ADAMTS13 gene in a patient with thrombotic thrombocytopenic purpura (TTP). Thrombosis Research, 2012, 130, S186.	1.7	0